<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6734211/results/search/funders/results.xml">
  <result pre="University of Bologna, [8], [9], 0000 0004 1757 2304 grid.8404.8" exact="Department of Health" post="Sciences, Section of Clinical Pharmacology and Headache Center, University"/>
  <result pre="CGRP ligand, eptinezumab, is currently under review by the US" exact="Food and Drug Administration" post="[ 70]. These macromolecule anti-CGRP/R antibodies have been specifically"/>
  <result pre="and travel grants from Allergan, Allmirall, Electrocore, Eli Lilly, Lusofarmaco," exact="Merck" post="&amp;amp; Co, New Penta, Novartis, Teva and Visufarma. P."/>
  <result pre="and support to attend national and international conferences from: Abbvie," exact="Bayer" post="Schering, Biogen-Dompè, Biogen-Idec, Eisai, Genzyme, Lundbeck, Lusofarmaco, Merck-Serono, Novartis,"/>
  <result pre="has received honoraria for speaking engagements or consulting activities with" exact="Allergan" post="Italia, AbbVie srl, Chiesi Farmaceutici, Eli Lilly, Novartis, Teva,"/>
  <result pre="honoraria for speaking engagements or consulting activities with Allergan Italia," exact="AbbVie" post="srl, Chiesi Farmaceutici, Eli Lilly, Novartis, Teva, UCB Pharma"/>
  <result pre="speaking engagements or consulting activities with Allergan Italia, AbbVie srl," exact="Chiesi Farmaceutici," post="Eli Lilly, Novartis, Teva, UCB Pharma S.p.A,, Zambon. F."/>
  <result pre="IBSA. L. Grazzi has received consultancy and advisory fees from" exact="Allergan" post="SpA, Electrocore LLC, Novartis, TEVA, ElyLilly. M. Leone has"/>
  <result pre="grants and travel grants from Allergan, Electrocore, Elythrapharma, Eli Lilly," exact="Novartis" post="and Teva. L. A. Pini has received fees for"/>
  <result pre="as well as research grants and travel grants from Allergan," exact="Novartis" post="and TEVA. M. P. Prudenzano has received fees for"/>
  <result pre="honoraria, as well as congress fee reimbursements from Allergan, Almirall," exact="Novartis" post="and Teva. P. Sarchielli has received fees for participation"/>
  <result pre="(fremanezumab) for injection: summary of product characteristics 2018 65. collab:" exact="Teva Pharmaceutical Industries" post="Ltd Ajovy™ (fremanezumab-vfrm) injection, for subcutaneous use 2018 66."/>
  <result pre="Ltd Ajovy™ (fremanezumab-vfrm) injection, for subcutaneous use 2018 66. collab:" exact="Eli Lilly and Company" post="Emgality (galcanezumab-glnm) injection, for subcutaneous use: US prescribing information"/>
  <result pre="(galcanezumab) for injection: summary of product characteristics 2018 68. collab:" exact="Novartis" post="Europharm Limited Aimovig (erenumab) for injection: summary of product"/>
  <result pre="(erenumab) for injection: summary of product characteristics 2018 69. collab:" exact="Amgen" post="Inc Aimovig™ (erenumab-aooe) injection, for subcutaneous use: US prescribing"/>
  <result pre="Agency (EMA) accepts fremanezumab marketing authorization application 2018 76. collab:" exact="Teva Pharmaceutical Industries" post="Ltd FDA accepts biologics license application for fremanezumab with"/>
 </snippets>
</snippetsTree>
